ENGLEWOOD, CO / ACCESSWIRE / April 5, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company centered on commercializing novel therapeutics and shopper health care solutions, these days announced the appointment of Richard Eisenstadt as Chief Money Officer. Mr. Eisenstadt is an accomplished pharmaceutical field executive with more than 20 a long time of practical experience in foremost finance and accounting functions, supporting scientific improvement and commercialization, and elevating money within just the life sciences sector.
Mr. Eisenstadt replaces David Inexperienced who has stepped down as Main Fiscal Officer as of March 31, 2021.
Mr. Eisenstadt most recently was Chief Economical Officer at Neos Therapeutics, Inc. exactly where he lifted more than $340 million in non-public and public equity and debt financings and supported the transition of the firm from scientific stage to commercial functions prior to its merger with Aytu in March 2021. Prior to Neos, Mr. Eisenstadt served as Main Monetary Officer at Arborgen, Inc., and prior to that, Main Economic Officer at Tranzyme, Inc., the place he led its IPO, negotiated several licensing agreements, and financed the enterprise through late-stage scientific advancement. Mr. Eisenstadt acquired an M.B.A. from James Madison College and a B.A. in Economics from the University of North Carolina at Chapel Hill.
“Rich’s deep knowledge with monetary organizing and accounting, boosting funds, investor relations, clinical advancement, and business operations will be a incredible asset to Aytu, in particular as we carry on to increase our business portfolio of prescription therapeutics and client overall health solutions and expand our enhancement pipeline. His appointment will come at a pivotal time for the enterprise, and we are extremely pleased to have him join the workforce,” commented Josh Disbrow, Chief Government Officer of Aytu BioPharma. “Also, as Dave departs the organization, the Board and I would like to express our honest gratitude to Dave for his lots of contributions and service to Aytu and desire him nicely.”
Mr. Eisenstadt commented, “I am honored to be asked to sign up for Aytu to guidance the combination of the Neos and Aytu branded prescription therapeutic portfolios. Collectively with Josh and the incumbent management workforce, I glimpse forward to continuing to make worth by means of both organic growth in our merchandise offerings and through strategic acquisitions of late-stage products candidates and on-sector belongings.”
About Aytu BioPharma, Inc.
Aytu BioPharma is a specialty pharmaceutical company with a rising industrial portfolio of prescription therapeutics and purchaser wellbeing products and solutions. The company’s primary prescription solutions handle interest deficit hyperactivity problem (ADHD) and other common pediatric ailments. Aytu markets ADHD goods Adzenys XR-ODT® (amphetamine) prolonged-release orally disintegrating tablets (see Entire Prescribing Info, like Boxed WARNING), Cotempla XR-ODT® (methylphenidate) prolonged-launch orally disintegrating tablets (see Comprehensive Prescribing Info, which include Boxed WARNING), and Adzenys-ER® (amphetamine) extended-release oral suspension (see Whole Prescribing Information, including Boxed WARNING). The company’s other pediatric items include things like Karbinal® ER (carbinoxamine maleate), an prolonged-release carbinoxamine (antihistamine) suspension indicated to treat quite a few allergic circumstances, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-primarily based prescription vitamin product lines made up of combinations of fluoride and natural vitamins in different formulations for infants and small children with fluoride deficiency. The firm’s evolution has been driven by strategic in-licensing, acquisition-primarily based transactions and organic products development. As Aytu proceeds this trajectory, the company is setting up a complimentary therapeutic advancement pipeline that will address considerable unmet demands. For additional information, you should go to aytubio.com.
Ahead-Seeking Statements
This push release incorporates forward-on the lookout statements in just the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Trade Act of 1934, or the Trade Act. All statements other than statements of historical info contained in this push launch, are ahead-searching statements. Forward-hunting statements are commonly penned in the future tense and/or are preceded by text these kinds of as ”may,” ”will,” ”should,” ”forecast,” ”could,” ”expect,” ”suggest,” ”believe,” ”estimate,” ”continue,” ”anticipate,” ”intend,” ”plan,” or equivalent text, or the negatives of this sort of phrases or other variants on this kind of conditions or comparable terminology. All statements other than statements of historic details contained in this presentation, are ahead-hunting statements, like but not confined to any statements relating to upcoming development of the company’s product or service offerings and growth of its progress and industrial pipeline. Remember to also refer to the dangers explained in ”Risk Factors” in Component I, Item 1A of Aytu’s Annual Report on Form 10-K and in the other reviews and paperwork it files with the Securities and Exchange Fee.
Get in touch with for Media and Investors:
Sarah McCabe
Stern Investor Relations, Inc.
[email protected]
Source: Aytu BioPharma, Inc.
See resource model on accesswire.com:
https://www.accesswire.com/638696/Aytu-BioPharma-Strengthens-Leadership-Team-with-Appointment-of-Richard-Eisenstadt-as-Chief-Fiscal-Officer
